Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004-2010

被引:51
|
作者
Dalton, Susanne O. [1 ]
Steding-Jesen, Marianne [2 ]
Jakobsen, Erik [3 ]
Mellemgaard, Anders [4 ]
Osterlind, Kell [5 ]
Schuz, Joachim [6 ]
Johansen, Christoffer [1 ,5 ]
机构
[1] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark
[2] Danish Canc Soc, Documentat & Qual, DK-2100 Copenhagen, Denmark
[3] Odense Univ Hosp, Dept Thorac Surg, Danish Lung Canc Registry, DK-5000 Odense, Denmark
[4] Herlev Univ Hosp, Dept Oncol, Copenhagen, Denmark
[5] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[6] Int Agcy Res Canc, Sect Environm & Radiat, F-69372 Lyon, France
关键词
SOCIAL-INEQUALITY; REHABILITATION; NAVIGATION; SURGERY; DENMARK; IMPACT; CARE;
D O I
10.3109/0284186X.2014.1001037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. To address social inequality in survival after lung cancer, it is important to consider how socioeconomic position (SEP) influences prognosis. We investigated whether SEP influenced receipt of first-line treatment and whether socioeconomic differences in survival could be explained by differences in stage, treatment and comorbidity. Material and methods. In the Danish Lung Cancer Register, we identified 13 045 patients with lung cancer diagnosed in 2004-2010, with information on stage, histology, performance status and first-line treatment. We obtained age, gender, vital status, comorbid conditions and socioeconomic information (education, income and cohabitation status) from nationwide population-based registers. Associations between SEP and receipt of first-line treatment were analysed in multivariate logistic regression models and those with overall mortality in Cox regression models with stepwise inclusion of possible mediators. Results. For both low-and high-stage lung cancer, adjusted ORs for first-line treatment were reduced in patients with short education and low income, although the OR for education did not reach statistical significance in men with high-stage disease. Patients with high-stage disease who lived alone were less likely to receive first-line treatment. The socioeconomic difference in overall survival was partly explained by differences in stage, treatment and comorbidity, although some differences remained after adjustment. Among patients with high-stage disease, the hazard ratio (HR) for death of those with low income was 1.12 (95% CI 1.05-1.19) in comparison with those with high income. Among patients with low-stage disease, those who lived alone had a 14% higher risk for dying (95% CI 1.05-1.25) than those who lived with a partner. The differences in risk for death by SEP were greatest in the first six months after diagnosis. Conclusion. Socioeconomic differences in survival after lung cancer are partly explained by social inequality in stage, first-line treatment and comorbidity. Efforts should be made to improve early diagnosis and adherence to first-line treatment recommendations among disadvantaged lung cancer patients.
引用
收藏
页码:797 / 804
页数:8
相关论文
共 50 条
  • [31] Overall survival throughout treatment course among patients diagnosed with small cell lung cancer.
    Estrin, Adina
    Prince, Patricia
    Supina, Dylan
    Ben-Joseph, Rami
    Boccuti, Anne
    Asubonteng, Kobby
    Fridman, Moshe
    Rengarajan, Badri
    Hanvesakul, Raj
    Taylor, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Effects of comorbidity and smoking on the survival of lung cancer patients - Reply
    Toh, Chee-Keong
    Lim, Wan-Teck
    Leong, Swan-Swan
    Tan, Eng-Huat
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5469 - 5469
  • [33] Comorbidity and survival for patients with advanced-stage non-small cell lung cancer
    Chrischilles, Elizabeth A.
    Abu Hejleh, Taher
    Carter, Knute D.
    Pendergast, Jane F.
    Halfdanarson, Thorvardur Ragnar
    Fletcher, Robert H.
    Wallace, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Survival Differences by Comorbidity Burden among Patients with Stage I/II Non-Small-Cell Lung Cancer after Thoracoscopic Resection
    Wheeler, Meghann
    Karanth, Shama D. D.
    Mehta, Hiren J. J.
    Yang, Danting
    Aduse-Poku, Livingstone
    Washington, Caretia
    Hong, Young-Rock
    Zhang, Dongyu
    Gould, Michael K. K.
    Braithwaite, Dejana
    CANCERS, 2023, 15 (07)
  • [35] Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer
    Jeremic, B
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (02): : 444 - 445
  • [36] Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer
    Battafarano, RJ
    Piccirillo, JF
    Meyers, BF
    Hsu, HS
    Guthrie, TJ
    Cooper, JD
    Patterson, GA
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (02): : 280 - 287
  • [37] Survival after surgery for lung cancer among patients with autoimmune diseases
    Nagano, Masaaki
    Cong, Yue
    Nakao, Keita
    Kawashima, Mitsuaki
    Konoeda, Chihiro
    Sato, Masaaki
    SURGERY TODAY, 2025, 55 (04) : 518 - 525
  • [38] Stage-specific conditional survival among young versus older adults with colorectal cancer in the United States, 2004-2010
    Sanford, Nina Niu
    Ahn, Chul
    Folkert, Michael Ryan
    Aguilera, Todd Anthony
    Sher, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] Comorbidity: Usage of, and survival after chemotherapy for advanced lung cancer.
    Mellemgaard, Anders
    Bredin, Philomena
    Iachina, Maria
    Green, Anders
    Krasnik, Mark
    Jakobsen, Erik
    Luechtenborg, Margreet
    Moller, Henrik
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Socioeconomic Factors and Readmission in Patients With Early-Stage Lung Cancer After Lobectomy
    Kawada, Tomoyuki
    ANNALS OF THORACIC SURGERY, 2017, 104 (03): : 1098 - 1098